NYSE · Hospital & Medical Service Plans
Quote as of Oct 9, 2:31 PM ET · delayed
Fairly Valued. Our fair value estimate is USD 304.50 against a price of USD 282.93, +8% implied upside. Reasoning and scenarios are in Cigna Group stock draws attention as growth meets a pharmacy squeeze.
Cigna Group declared USD 6.04 per share in dividends in FY2025, up 7.9% from USD 5.60 in FY2024. At USD 282.93 that is a 2.13% trailing yield. The dividend took 27% of FY2025 diluted EPS of USD 22.18.
Cigna Group stock is getting fresh attention, but the evidence does not pin today’s move on a specific event. Its latest disclosed results show stronger earnings and a higher 2026 outlook alongside pressure in pharmacy-benefit profits.
StockLarge CapHealthcareNo earnings notes for this company yet.
Revenue (USD, billions)
Margins (%)
Free cash flow (USD, billions)
Estimated ROIC (%)
Net debt (USD, billions)
Monetary values are in USD; revenue, FCF and net debt are in billions; EPS is per share. Missing values appear as gaps and “Not available.” Source: SEC EDGAR XBRL filings, latest restated values; quarterly cash flow derived from year-to-date figures; Q4 = fiscal year minus nine months. ROIC is NOPAT (21% tax) over debt plus equity.
| Period | Revenue | Gross % | Op % | FCF | EPS | ROIC % | Net debt |
|---|---|---|---|---|---|---|---|
| FY2016 | 39.8 | Not available | 7.75 | 3.56 | 7.19 | Not available | Not available |
| FY2017 | 41.8 | Not available | 9.43 | 3.62 | 8.77 | Not available | Not available |
| FY2018 | 48.6 | Not available | 8.55 | 3.24 | 10.5 | 4.08 | 35.7 |
| FY2019 | 153.6 | Not available | 5.26 | 8.44 | 13.4 | Not available | Not available |
| FY2020 | 160.4 | Not available | 5.08 | Not available | 23.0 | Not available | Not available |
| FY2021 | 174.1 | Not available | 4.56 | Not available | 15.8 | Not available | Not available |
| FY2022 | 180.5 | Not available | 4.68 | Not available | 21.4 | Not available | Not available |
| FY2023 | 195.3 | Not available | 4.37 | Not available | 17.4 | Not available | Not available |
| FY2024 | 247.1 | Not available | 3.81 | Not available | 12.1 | Not available | Not available |
| FY2025 | 274.9 | Not available | 3.35 | Not available | 22.2 | Not available | Not available |
Current price
USD 282.93
Fair value estimate
USD 304.50
Implied upside
+7.6%
Bear
25%USD 245
Direct equity valuation using assumed adjusted EPS multiplied by an assumed P/E; quote currency USD.
The lower case assumes pharmacy-benefit earnings remain pressured and the business earns a lower multiple. The company’s outlook is management guidance, not a guaranteed result.
Base
55%USD 305
Direct equity valuation using assumed adjusted EPS multiplied by an assumed P/E; quote currency USD.
The base case uses the company’s minimum adjusted EPS outlook and a 10.0x assumed multiple. The unrounded calculation is $30.45 × 10.0 = $304.50 per share, rounded to $305.
Bull
20%USD 365
Direct equity valuation using assumed adjusted EPS multiplied by an assumed P/E; quote currency USD.
The upside case assumes the company exceeds its outlook floor, pharmacy-benefit earnings recover and the market assigns a higher multiple. Those are analyst assumptions, not disclosed company guidance.
No news items logged for this company yet.